Ask-RX

About Ask-RX

Ask Rx is a 2023-founded telehealth provider that distinguishes itself by offering both compounded semaglutide and brand-name Zepbound (tirzepatide) at prices ranging from $149 to $299 per month. The inclusion of Zepbound, Eli Lilly’s FDA-approved tirzepatide for weight loss, alongside compounded options is a notable differentiator. Few providers in this price range offer a brand-name pathway, and the 9 entry point for compounded semaglutide is among the lowest in the market.

Ask Rx’s most promoted feature is its 24/7 prescription support, meaning patients can reach a support team at any hour for questions about their medication, side effects, or treatment plan. In an industry where “we’ll get back to you in 24-48 hours” is the norm, around-the-clock availability is a significant clinical and practical advantage. For patients experiencing side effects or dosing questions outside business hours, this access can provide meaningful reassurance and potentially better health outcomes.

The company’s Trustpilot profile is nascent, with a 4.0-star rating from just 10+ reviews. At this volume, the rating is essentially a placeholder and should not be relied upon for decision-making. The reviews that do exist are mixed, with some patients praising the service and others noting areas for improvement. As Ask Rx grows, its Trustpilot profile will become a more useful data point. The company does not currently have a BBB listing, which is common for newer providers but limits third-party accountability visibility.

The availability of brand-name Zepbound deserves emphasis. Tirzepatide has demonstrated strong efficacy in clinical trials, with the SURMOUNT trials showing average weight loss of approximately 20% of body weight. Accessing this medication through a telehealth provider at a potentially lower cost than traditional pharmacy channels is a genuine value proposition. However, patients should confirm current Zepbound pricing and availability directly with Ask Rx, as brand-name supply and pricing can fluctuate.

Ask Rx is a young provider with an ambitious feature set. The combination of 24/7 support, brand-name access, and aggressive entry-level pricing creates a compelling pitch. The risk is that the company is too new to have a proven operational track record, and its review volume is too small to validate the experience at scale. Our editorial team is cautiously optimistic but advises patients to verify current offerings and monitor the company’s review trajectory as it matures.

At a Glance